Pinetree Therapeutics is a Cambridge, Massachusetts biotech founded in 2019 that develops antibody-based targeted protein degraders for cancer. Its AbReptor and TAER-TAB platforms use modular bispecific and multispecific antibodies to hijack the body's own lysosomal machinery and eliminate disease-driving membrane-bound and extracellular proteins - including drug-resistant receptor tyrosine kinases that conventional inhibitors cannot reach. Led by founder and CEO Ho-Juhn Song, Ph.D., the preclinical company has raised roughly $111M to date, struck a $500M+ EGFR-degrader option deal with AstraZeneca, and is advancing lead oncology programs toward Phase I.
Plexium is a San Diego precision medicine company designing small-molecule protein degraders - monovalent direct degraders and molecular glues - that switch off disease-driving proteins traditionally considered undruggable. Its DELTA Discovery platform runs ultra-high-throughput cell-based screening to find and optimize new degrader chemistry across cancer and neurological disease.
Neomorph is a San Diego clinical-stage biotech building molecular glue degraders - small molecules that recruit the cell's own disposal machinery to destroy disease-driving proteins long written off as 'undruggable.' Founded in 2020 out of Deerfield Management with scientific founders who decoded how thalidomide-class drugs work, the company has assembled what it calls the world's largest proprietary molecular glue target space across a broad portfolio of E3 ubiquitin ligases. It has signed multibillion-dollar discovery pacts with AbbVie, Novo Nordisk, and Biogen, dosed its first patient with lead candidate NEO-811 in kidney cancer, and raised roughly $209M across Series A and B.